www.dailypolitical.com ·
rigel pharmaceuticals nasdaqrigl issues earnings results
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedRigel Pharmaceuticals (RIGL) reported earnings miss with lower revenue and EPS vs expectations, but product sales growth of 26% YoY and maintained guidance suggest underlying commercial traction. The RIPK1 program regain from Lilly is a minor strategic move. Impact is company-specific, not sector-wide. Weak commercial mechanism: earnings miss is a single-company event with no clear supply/demand/regulatory channel affecting the broader biotech sector.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Rigel Pharmaceuticals reported Q1 2026 EPS of -$0.44, missing consensus of -$0.80.
- Revenue was $58.82 million, below $62.40 million forecast.
- Net product sales grew 26% YoY to $54.9 million, driven by TAVALISSE and REZLIDHIA.
- Company maintained 2026 revenue guidance of $275M-$290M and aims for net income profitability.
- Rigel will regain the RIPK1 program from Lilly effective June 15, 2026.
Rigel Pharmaceuticals stock likely to decline 1-3% in 48h on earnings miss and revenue shortfall.
Sign in to see all sector verdicts, full thesis and counter-argument debate.